Nothing Special   »   [go: up one dir, main page]

WO2011050206A3 - Compositions and methods for the treatment of sinonasal disorders - Google Patents

Compositions and methods for the treatment of sinonasal disorders Download PDF

Info

Publication number
WO2011050206A3
WO2011050206A3 PCT/US2010/053616 US2010053616W WO2011050206A3 WO 2011050206 A3 WO2011050206 A3 WO 2011050206A3 US 2010053616 W US2010053616 W US 2010053616W WO 2011050206 A3 WO2011050206 A3 WO 2011050206A3
Authority
WO
WIPO (PCT)
Prior art keywords
sinonasal
compositions
treatment
methods
disorders
Prior art date
Application number
PCT/US2010/053616
Other languages
French (fr)
Other versions
WO2011050206A2 (en
Inventor
Jay Lichter
Carl Lebel
Fabrice Piu
Jeffrey P. Harris
Original Assignee
Otonomy, Inc.
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otonomy, Inc., The Regents Of The University Of California filed Critical Otonomy, Inc.
Publication of WO2011050206A2 publication Critical patent/WO2011050206A2/en
Publication of WO2011050206A3 publication Critical patent/WO2011050206A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

Disclosed herein are compositions and methods for the treatment of sinonasal and/or nasopharyngeal diseases or conditions with active agent compositions and formulations administered locally to an individual afflicted with a sinonasal or nasopharyngeal disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted sinonasal structure(s).
PCT/US2010/053616 2009-10-21 2010-10-21 Compositions and methods for the treatment of sinonasal disorders WO2011050206A2 (en)

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US25378209P 2009-10-21 2009-10-21
US61/253,782 2009-10-21
US25537909P 2009-10-27 2009-10-27
US61/255,379 2009-10-27
US25578309P 2009-10-28 2009-10-28
US25578009P 2009-10-28 2009-10-28
US61/255,783 2009-10-28
US61/255,780 2009-10-28
US29713810P 2010-01-21 2010-01-21
US29717010P 2010-01-21 2010-01-21
US61/297,138 2010-01-21
US61/297,170 2010-01-21
US36428710P 2010-07-14 2010-07-14
US61/364,287 2010-07-14
US36667710P 2010-07-21 2010-07-21
US61/366,677 2010-07-22

Publications (2)

Publication Number Publication Date
WO2011050206A2 WO2011050206A2 (en) 2011-04-28
WO2011050206A3 true WO2011050206A3 (en) 2011-09-22

Family

ID=43900967

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2010/053217 WO2011049960A2 (en) 2009-10-21 2010-10-19 Compositions and methods for the treatment of sinonasal disorders
PCT/US2010/053616 WO2011050206A2 (en) 2009-10-21 2010-10-21 Compositions and methods for the treatment of sinonasal disorders

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2010/053217 WO2011049960A2 (en) 2009-10-21 2010-10-19 Compositions and methods for the treatment of sinonasal disorders

Country Status (1)

Country Link
WO (2) WO2011049960A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT1962805T (en) 2005-12-08 2016-10-25 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections
AU2012211514B2 (en) * 2006-10-24 2014-07-31 Aradigm Corporation Concentrated, inhalable ciprofloxacin formulation
US8119156B2 (en) 2006-10-24 2012-02-21 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
CN103874481B (en) 2011-07-13 2016-09-28 铸造有限责任公司 For delivering the method and device of therapeutic agent to mucous membrane of nasopharynx target
WO2013176622A1 (en) * 2012-05-21 2013-11-28 Agency For Science, Technology And Research (A*Star) A dry powder formulation
ES2743039T3 (en) 2012-11-29 2020-02-18 Insmed Inc Vancomycin stabilized formulations
DE202013000748U1 (en) 2013-01-24 2013-02-19 Merz Pharma Gmbh & Co. Kgaa Sprayable liquid preparation for especially nasal application with increased local residence time
EP2759290B1 (en) 2013-01-24 2019-11-06 Merz Pharma GmbH & Co. KGaA Sprayable liquid composition for nasal application having an increased local retention time
DE102013001151A1 (en) 2013-01-24 2014-07-24 Merz Pharma Gmbh & Co. Kgaa Nasal preparation, used to topical, protective, nurturing/supporting application to treat irritation/swelling in nasal mucosa due to e.g. allergies, includes mineral salt, water, alcohols, poloxamer surfactants, and additives e.g. enzyme
US20140371305A1 (en) * 2013-06-14 2014-12-18 Professional Compounding Centers Of America Mupirocin Antibiotic Composition
US20150164882A1 (en) 2013-07-22 2015-06-18 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20160279055A1 (en) 2013-07-22 2016-09-29 Imprimis Pharmaceuticals, Inc. Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
US9987227B2 (en) 2013-10-22 2018-06-05 Aradigm Corporation Inhaled surfactant-modified liposomal formulations providing both an immediate and sustained release profile
DK3466432T3 (en) 2014-05-15 2020-09-28 Insmed Inc PROCEDURES FOR THE TREATMENT OF PULMONAL NON-TUBERCULOSE MICOBACTERIAL INFECTIONS
EP3164115A4 (en) 2014-07-03 2017-05-17 Otonomy, Inc. Sterilization of ciprofloxacin composition
CN104341405B (en) * 2014-09-25 2016-09-14 武汉大学 Preparation method and application of a compound with activity of inhibiting Aβ aggregation
WO2017105356A1 (en) 2015-12-18 2017-06-22 Ak-Kim Kimya Sanayi Ve Ticaret Anonim Sirketi Hollow fiber membrane module
CN105902543B (en) * 2016-04-28 2019-02-12 华北制药股份有限公司 A kind of high-purity mezlocillin sodium preparation and preparation method thereof
US20180071281A1 (en) * 2016-08-19 2018-03-15 Gerbe Labs Inc. Treating chronic rhinosinusitis
WO2019191627A1 (en) 2018-03-30 2019-10-03 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
CN110141559A (en) * 2019-06-18 2019-08-20 浦易（上海）生物技术有限公司 It is a kind of for the pastille slow-release particle of schneiderian membrane and its application
WO2021207305A1 (en) * 2020-04-08 2021-10-14 Nostrum Pharmaceuticals, Llc Compositions and methods using interferon for treating viral respiratory infections
US20220135653A1 (en) * 2020-11-05 2022-05-05 Bravado Pharmaceuticals, LLC Intranasal Antiviral Therapy for Mucosal Protection Against Virus Infections
CN113456580B (en) * 2021-07-21 2024-03-22 沈阳化工大学 Resveratrol in-situ gel preparation and characterization method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0131315A2 (en) * 1983-05-13 1985-01-16 ISTITUTO DE ANGELI S.p.A. Nasal preparations comprising anticholinergic quaternary ammonium salts
US5935604A (en) * 1993-05-20 1999-08-10 Danbiosyst Uk Limited Nasal drug delivery composition containing nicotine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0131315A2 (en) * 1983-05-13 1985-01-16 ISTITUTO DE ANGELI S.p.A. Nasal preparations comprising anticholinergic quaternary ammonium salts
US5935604A (en) * 1993-05-20 1999-08-10 Danbiosyst Uk Limited Nasal drug delivery composition containing nicotine

Also Published As

Publication number Publication date
WO2011050206A2 (en) 2011-04-28
WO2011049960A2 (en) 2011-04-28
WO2011049960A9 (en) 2011-08-18

Similar Documents

Publication Publication Date Title
WO2011050206A3 (en) Compositions and methods for the treatment of sinonasal disorders
WO2010011609A3 (en) Controlled release antimicrobial compositions and methods for the treatment of otic disorders
WO2010074992A3 (en) Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
WO2011049958A3 (en) Modulation of gel temperature of poloxamer-containing formulations
WO2010008995A3 (en) Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders
WO2010011466A3 (en) Controlled-release cns modulating compositions and methods for the treatment of otic disorders
WO2010011605A3 (en) Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
WO2012103038A3 (en) Nanoparticle compositions, formulations thereof, and uses therefor
WO2012145133A3 (en) Occlusion-crossing devices, imaging, and atherectomy devices
EP4327888A3 (en) Oral formulations of cytidine analogs and methods of use thereof
WO2012083017A3 (en) Controlled release oral dosage forms of poorly soluble drugs and uses thereof
WO2010151755A3 (en) TREATMENT OF INFLAMMATORY DISEASES USING miR-124
EA201270221A1 (en) TREATMENT OF CROWN DISEASE WITH LACQUINIMODE
WO2010083239A3 (en) Therapeutic modulation of vaginal epithelium boundary lubrication
EA202091999A3 (en) APPLICATION OF DPP IV INHIBITORS
EP2358378A4 (en) Topical formulation(s) for the treatment of inflammation, skin and mucosal disorders and other diseases thereof
WO2013052647A3 (en) Formulations and uses of retinoic acid receptor selective agonists
IL201479A (en) Use of tapentadol for the manufacture of a medicament for the treatment of pain
MX2016002408A (en) Treatment of pediatric otic disorders.
WO2009109613A3 (en) 1-BENZYL-3-HYDROXYMETHYLINDAZOIιE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1
WO2011119227A3 (en) Compositions for the treatment of central nervous system disorders including depression employing novel drug combination therapy to reduce suicidality in patients
MY166890A (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EE05761B1 (en) Combined pharmaceutical composition for the treatment of diabetes and metabolic disorders
WO2009109616A8 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
WO2014107730A3 (en) Use of fatty acid niacin conjugates for treating diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10825702

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10825702

Country of ref document: EP

Kind code of ref document: A2